These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 13972853)

  • 1. Studies on fibrinolysis. I. A circulating substance capable of converting plasmin-sensitive to plasmin-resistant clots.
    RABINER SF; ROBBINS KC
    Proc Soc Exp Biol Med; 1962 Dec; 111():701-6. PubMed ID: 13972853
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins.
    Jian JW; Chiu WC; Chang HT; Hsu PH; Huang CC
    Anal Chim Acta; 2013 Apr; 774():67-72. PubMed ID: 23567118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis. II. Evaluation of enzymatic thrombolysis: Experiments with plasmin preparations in arterial, venous thrombosis.
    NAHUM LH; KLINE D; FISHBEIN R
    Conn Med; 1960 Mar; 24():139-46. PubMed ID: 14425837
    [No Abstract]   [Full Text] [Related]  

  • 5. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
    Galanakis DK; Neerman-Arbez M; Kudryk B; Henschen A
    Blood Coagul Fibrinolysis; 2010 Mar; 21(2):135-9. PubMed ID: 20019599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of plasmin system. II. Fibrinolysis and plasmin (activator)--inhibitor ratio.
    MAKI M; NAGASAWA K
    Tohoku J Exp Med; 1963 Jan; 78():363-9. PubMed ID: 13932347
    [No Abstract]   [Full Text] [Related]  

  • 8. Return to normal of 99mTc-plasmin test after deep venous thrombosis and its relationship to vessel wall fibrinolysis.
    Edenbrandt CM; Hedner U; Nilsson J; Ohlin P; Tengborn L
    Eur J Nucl Med; 1986; 12(4):197-200. PubMed ID: 2945723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A STANDARD CLOT METHOD FOR THE ASSAY OF PLASMINOGEN ACTIVATORS, ANTI-ACTIVATORS, AND PLASMIN.
    HAWKEY CM; STAFFORD JL
    J Clin Pathol; 1964 Mar; 17(2):175-81. PubMed ID: 14149945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of plasminogen, plasmin, and plasminogen activators in the migration of fibroblasts into plasma clots.
    Knox P; Crooks S; Scaife MC; Patel S
    J Cell Physiol; 1987 Sep; 132(3):501-8. PubMed ID: 2958486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogenolytic and fibrinolytic activity of cell-associated plasmin.
    Humphries JE; Vasudevan J; Gonias SL
    Arterioscler Thromb; 1993 Jan; 13(1):48-55. PubMed ID: 7678497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.
    Westbury SK; Duval C; Philippou H; Brown R; Lee KR; Murden SL; Phillips E; Reilly-Stitt C; Whalley D; Ariëns RA; Mumford AD
    Thromb Haemost; 2013 Dec; 110(6):1135-44. PubMed ID: 24048413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis.
    Teger-Nilsson AC; Gyzander E; Myrwold H; Noppa H; Olsson R; Wallmo L
    Haemostasis; 1978; 7(2-3):155-7. PubMed ID: 149047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
    Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E
    FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Kinetics of in vitro fibrinolysis by plasmin and a plasmin-streptokinase equimolar complex].
    Aĭsina RB; Zhitkova IuV; Eremeev NL; Popova GIu; Kazanskaia NF
    Ukr Biokhim Zh (1978); 1991; 63(1):20-6. PubMed ID: 1827551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
    Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin.
    Yang CD; Hwang KK; Yan W; Gallagher K; FitzGerald J; Grossman JM; Hahn BH; Chen PP
    J Immunol; 2004 May; 172(9):5765-73. PubMed ID: 15100323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasminogen activation and regulation of fibrinolysis].
    Madoiwa S
    Nihon Rinsho; 2014 Jul; 72(7):1218-23. PubMed ID: 25163311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of arterial clots. Using fibrinolysin in an isolation perfusion system.
    Wagner DE; Polishook RD; Baue AE; Blakemore WS
    Arch Surg; 1965 Nov; 91(5):712-5. PubMed ID: 4221212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.